

Characterization of Zinc- α_2 -Glycoprotein as a Cell Adhesion Molecule That Inhibits the Proliferation of an Oral Tumor Cell Line

Gang Lei,¹ Henry Brysk,¹ Istvan Arany,² Stephen K. Tyring,^{1,2} Ganesan Srinivasan,³ and Miriam M. Brysk^{1,2,3*}

¹Department of Dermatology, University of Texas Medical Branch, Galveston, Texas 77555

²Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas 77555

³Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas 77555

Abstract Zn- α_2 -glycoprotein (Zn α_2 gp) is a soluble protein widely distributed in body fluids and glandular epithelia. We have found it to be expressed in stratified epithelia as well. Zn α_2 gp is clinically correlated with differentiation in various epithelial tumors, including oral and epidermal tumors. We have cloned epidermal Zn α_2 gp and report the preparation of the recombinant protein in a Baculovirus expression system. Like the native molecule, recombinant Zn α_2 gp has RNase activity. Zn α_2 gp functions as a matrix protein for the Tu-138 oral squamous cell carcinoma cell line. Cell attachment to Zn α_2 gp is comparable to that for fibronectin and is inhibited by the synthetic RGD peptides RGD, RGDV, and RGDS. Attachment is also inhibited by the antibody to integrin $\alpha_5\beta_1$ (the fibronectin receptor), but not by antibodies to integrins $\alpha_v\beta_3$, $\alpha_3\beta_1$, and $\alpha_2\beta_1$. We find that the proliferation of Tu-138 cells is inhibited on a Zn α_2 gp matrix, as compared with other matrix proteins (fibronectin, vitronectin, laminin, and collagens I and IV) on which growth resembles that on the BSA control. We believe that the role of Zn α_2 gp in differentiation and its RNase activity are two likely suspects as agents of the inhibition of proliferation. *J. Cell. Biochem.* 75:160–169, 1999. © 1999 Wiley-Liss, Inc.

Key words: cell attachment; cell growth; cell-matrix interactions; integrins; cell-surface receptors

Zinc- α_2 -glycoprotein (Zn α_2 gp) was initially purified from plasma [Bürgi and Schmid, 1961]; it can be precipitated by adding zinc ions and it displays electrophoretic mobility in the α_2 -region of the plasma globulins, hence its name. It has been detected in most body fluids, including blood, seminal plasma, breast milk, synovial fluid, saliva, urine, and sweat [Poortmans and Schmid, 1968; Frenette et al., 1987; Ohkubo et al., 1990; Sánchez et al., 1992]. The antibody to this protein labels a wide variety of

secretory epithelia in various human glands [Tada et al., 1991]. Northern blot analysis shows the gene to be expressed in liver, breast, prostate, kidney, pancreas, and several tumors [Schmid and Takahashi, 1964; Freije et al., 1991]. Zn α_2 gp has been cloned and the complete genomic sequence determined for prostate [Ueyama et al., 1993] and breast [Freije et al., 1993]. The cDNAs differ only in some minor substitutions and are ascribed to a single active gene and one or two pseudogenes. The corresponding amino acid sequences appear to be similar for these two tissues, as well as for blood plasma [Araki et al., 1988], consisting of a single polypeptide chain of 278 amino acids. The molecular weight is within the range 38–41 kDa, depending on the tissue; its fluctuation is associated with variations in glycosylation in different tissues, mostly about 12–18% carbohydrate, except that seminal plasma is unglycosylated [Ohkubo et al., 1990]. Direct sequenc-

Abbreviations used: BSA, bovine serum albumin; DMEM, Dulbecco's minimal essential medium; DPBS, Dulbecco's phosphate-buffered saline; FBS, fetal bovine serum; RGD, Arg-Gly-Asp peptide sequence; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; Zn α_2 gp, zinc- α_2 -glycoprotein.

*Correspondence to: Miriam M. Brysk, Department of Dermatology, University of Texas Medical Branch, Galveston, TX 77555-0783

Received 29 January 1999; Accepted 14 April 1999

ing of Zn α_2 gp is blocked at its N-amino acid terminus, pyroglutamic acid [Araki et al., 1988], again except in seminal plasma. We have found that Zn α_2 gp is also expressed in stratified epithelia; in particular, we have cloned it from epidermal keratinocytes and found a nucleotide sequence identical to that from prostate, differing only in posttranslational modifications [Lei et al., 1997].

Despite the widespread occurrence of Zn α_2 gp in different body tissues and the extensive studies of its molecular, protein, and crystalline structure [Sánchez et al., 1997], there are remarkably few clues to its function. Although Zn α_2 gp has considerable (36–39%) homology with major histocompatibility complex (MHC) class I α chains in its amino acid sequence and domain structure [Araki et al., 1988], the consequent suspicion that it plays an immunological role has not been substantiated. Zn α_2 gp has been used extensively as a clinical marker of the histological grade of breast cancer tumors [Diez-Itza et al., 1993] and in prostate cancer [Frenette et al., 1987]. Higher levels of Zn α_2 gp are observed in the better differentiated cells, but without mechanistic explanation. We have confirmed these trends for normal epidermal and oral epithelia [Brysk et al., 1997a] and for oral squamous cell carcinomas [Brysk et al., 1999]. We have shown that Zn α_2 gp has ribonuclease activity against single-stranded RNA and preferentially cleaves RNA at its pyrimidine residues [Lei et al., 1998]. A human renal cell carcinoma line was found to attach and spread on a coating of Zn α_2 gp, while melanoma, breast carcinoma, prostatic adenocarcinoma, and osteosarcoma cell lines exhibited little or no binding [Takagaki et al., 1994]. We have investigated the matrix protein properties of Zn α_2 gp on the Tu-138 oral squamous cell carcinoma cell line. We report the preparation of recombinant Zn α_2 gp, its effect on the adhesion and proliferation of the cells (as compared with other matrix proteins), and the determination of the integrin receptor for Zn α_2 gp.

MATERIALS AND METHODS

Preparation of Recombinant Zn α_2 gp in a Baculovirus Expression System

Full-length Zn α_2 gp cDNA was cloned from our epidermal keratinocyte cDNA library [Lei et al., 1997]. To obtain restriction enzyme cuts compatible with the multiple cloning site of the Baculovirus expression vector PVL 1392, at

each flank of the Zn α_2 gp cDNA, the cDNA was amplified by polymerase chain reaction (PCR) using two primers for the sense and antisense oligonucleotides: 5'-GATCAGATCTGCAGCAAGAATGGTGCCTGTC-3' and 5'-CCTTC-TAGAAAGCTAGGCAAGGAGGGATG-3'.

PCR was performed for 30 cycles, each consisting of a denaturation step at 94°C for 1 min, a reannealing at 60°C for 1 min, and an extension at 72°C for 2 min. The PCR products were fractionated on a 1% agarose gel and further purified using the QIAquick Gel Extraction kit (QIAGEN, Valencia, CA). The pure cDNA was doubly digested with the restriction enzymes *Bgl*II and *Xba*I, then inserted into the vector PVL1392 previously digested with the same enzymes downstream of the polyhefrin promoter. The vector PVL1392, containing the Zn α_2 gp cDNA, was subcloned into DH5 α competent cells (Life Technologies, Gaithersburg, MD) according to the procedure recommended by the manufacturer. In order to generate the recombinant Baculovirus, 2 μ g of PVL1392 vector, containing the full-length Zn α_2 gp cDNA, was mixed with 0.2 μ g of BaculoGold Baculovirus DNA in the presence of 0.75 ml of the transfection buffer A (PharMingen, San Diego, CA). The transfection mixture was added dropwise to a monolayer of Sf 9 insect cells cultured in the TMN-FH insect medium (PharMingen). The cells were kept at 27°C for 4 h; the medium was then removed from the co-transfection plate. The cells were washed twice with 3 ml of fresh TMN-FH medium and maintained in the fresh medium for 3–5 days before harvesting. A time-course study was conducted at 36, 48, 60, 72, and 80 h postinfection, to assess optimal protein production. The cells were pelleted by centrifugation at 1,200*g* for 10 min, resuspended in 10 mM TE buffer (pH 8.0), and then centrifuged at 2,500*g* for 15 min. The supernatant containing the recombinant Zn α_2 gp was further centrifuged at 4,000*g* for 15 min at 4°C.

Purification of Recombinant Zn α_2 gp

The purification procedure for Zn α_2 gp was previously described by us [Lei et al., 1997]. Briefly, the extract containing recombinant Zn α_2 gp was dialyzed against water for 16 h at 4°C. The extract was then poured into a slurry of Con A-Sepharose in a buffer of 10 mM HEPES, pH, 8.0, containing 0.5 mM MnCl₂, 0.5 mM CaCl₂, 0.5 mM NaCl, and 0.1% NaN₃, then gently rotated on a nutator for 16 h at 4°C. The

unbound proteins were removed by extensively washing the sepharose gel with the Con A buffer, and the absorbed glycoproteins were eluted with 1 M α -methyl-D-mannoside. The eluent was first dialyzed overnight at 4°C against Tris-acetate buffer, then concentrated in a Filtron Omega cell unit (22 μ m). The glycoproteins were further fractionated by gel-filtration high-performance liquid chromatography (HPLC) on a G-3000 SWDX high-resolution HPLC analytical column. The 35- to 45-kDa fractions containing Zn α_2 gp were then pooled, concentrated, and stored in 100 mM Tris-HCl, pH 7.4. Native Zn α_2 gp was isolated from human epidermis as previously described [Lei et al., 1997] and then purified by the same procedures as the recombinant molecule. Zn α_2 gp antiserum and prostate Zn α_2 gp were gifts from Dr. I. Ohkubo.

Western Blotting

Prostate Zn α_2 gp and epidermal native and recombinant Zn α_2 gp were analyzed by electrophoresis on 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels and stained with Coomassie blue. A duplicate gel was electrophoretically transferred to a nitrocellulose membrane in a buffer of 20% methanol, 25 mM Tris-HCl, and 192 mM glycine. The blots were quenched in TBST (10 mM Tris-HCl, pH 8.8, 150 mM NaCl, 0.05% Tween 20), containing 3% nonfat dried milk, for 30 min and then washed twice for 10 min in the buffer alone. The blot was then incubated for 1 h with a 1:500 dilution of rabbit anti-prostate Zn α_2 gp IgG in 0.5% dried milk in TBST and then washed twice for 10 min each with un-supplemented TBST. The blot was then incubated for 1 h in a 1:500 dilution of peroxidase-conjugated sheep anti-rabbit IgG (Cappel, ICN Biomedicals, Costa Mesa, CA), and the color was developed by the ECL (Enhanced Chemiluminescence) kit (Amersham Life Science, Arlington Heights, IL).

Zymography

Samples of prostate Zn α_2 gp and epidermal native and recombinant Zn α_2 gp were separated on a 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel (20 μ g/lane). The RNase activities were assayed by zymography, by a slight modification of a published protocol [Bravo et al., 1994]. Briefly, human epidermal total RNA, together with 2 mM EDTA, was added to the SDS-PAGE separating gel. After electrophoresis, the gel was washed

twice for 20 min in 10 mM Tris-HCl, pH 8.0, also containing 20% isopropanol, under gentle shaking, followed by two 20-min washes in 10 mM Tris-HCl, pH 8.0, all at room temperature. The gel was then incubated in a buffer of 100 mM Tris-HCl, pH 8.0, and stained for 5 min with 0.5 μ g/ml ethidium bromide. The bands were visualized under ultraviolet (UV) light and photographed.

Cell Culture

We used the Tu-138 squamous cell carcinoma cell line, derived from a gingival tumor [Liu et al., 1994]. It was grown and maintained in Dulbecco's minimal essential medium (DMEM)-F12 (1:1) supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin. Tissue culture media and FBS were obtained from Gibco-BRL Life Technologies (Grand Island, NY).

Cell Attachment and Spreading

Ninety-six-well plates were coated overnight at 4°C with dilutions (10–50 μ g/ml) of individual matrix proteins: Matrigel, collagen IV (Collaborative Research, Bedford, MA); laminin, vitronectin (Chemicon, Temecula, CA); fibronectin, collagen I (Sigma Chemical Co., St. Louis, MO); and recombinant Zn α_2 gp. The wells were blocked by incubation for 30 min with 3% heat-denatured bovine serum albumin (BSA) in Dulbecco's phosphate-buffered saline (DPBS), then rinsed 3 times with DPBS. Cultured Tu-138 cells were detached from the culture vessels by incubation with a solution of 0.025% trypsin-0.025% EDTA in DPBS, washed in culture medium containing 10% FBS, and then in the medium alone without serum. The cells were counted in a hemacytometer and adjusted to a concentration of 1×10^5 cells per ml. Aliquots (100 μ l) of the cells suspension were seeded onto the matrix-coated wells of the plate and allowed to attach for 2 h at 37°C in a 5% CO₂ incubator. Unbound cells were removed by gently washing the wells four times with warm DMEM, rinsed with DPBS, and assessed by the MTT assay (described below). Selected wells were photographed under a phase-contrast microscope to measure cell spreading.

MTT Assay of Cell Growth

Cell numbers in 96-well plates were determined by the MTT assay [Takagaki et al., 1994].

After aspiration of nonattached cells and culture medium, the wells were filled with 100 μ l of serum-free medium containing 25 μ l (5 mg/ml in DPBS) of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma) and incubated for 4 h at 37°C. The insoluble dye product was solubilized overnight at 37°C with 10% SDS containing 0.01 N HCl. Conversion of MTT to the formazan by metabolically viable cells was measured at 450 nm in a microplate reader (THERMA MAX, Molecular Devices, Sunnyvale, CA). Experiments were performed in triplicate.

Assay of Inhibition of Cell Attachment

Ninety-six-well plates were coated with Zn α_2 gp (at 20 μ g/ml) as described above. We used the RGD, RGDS, and REDV synthetic peptides (Bachem, Torrance, CA) to assess inhibition of cell attachment to recombinant Zn α_2 gp. We also used antibodies against $\alpha_5\beta_1$, $\alpha_v\beta_3$, $\alpha_3\beta_1$, and $\alpha_2\beta_1$ to assess which integrins were involved in cell adhesion to Zn α_2 gp. Cell numbers were determined by the MTT assay in triplicate wells.

Effect of Zn α_2 gp on Cell Proliferation

Ninety-six-well plates were coated with 20 μ g/ml of Zn α_2 gp, fibronectin, vitronectin, laminin, collagen I, collagen IV, and BSA, as described above. Tu-138 cells were adjusted to a concentration of 1×10^5 cells per ml, and aliquots (100 μ l) of the cell suspension were seeded onto the matrix-coated wells. The cells were allowed to attach for 4 h at 37°C in a 5% CO $_2$ incubator. Unattached cells were removed, and complete medium containing 10% FBS was then added. Cell growth was measured daily for 4 days by the MTT assay in triplicate wells.

RESULTS

Preparation and Purification of Recombinant Zn α_2 gp

We prepared recombinant Zn α_2 gp in a Baculovirus expression system. Zn α_2 gp was easily purified from the crude insect extract by Con A affinity chromatography and gel filtration. Figure 1 compares the following on SDS-PAGE: (Fig. 1A) prostate Zn α_2 gp, (Fig. 1B) native epidermal Zn α_2 gp, and (Fig. 1C) recombinant epidermal Zn α_2 gp. Lanes A1, B1, and C1 display SDS-PAGE gels stained with Coomassie blue, showing the migration of each variety of Zn α_2 gp.




Fig. 1. Identification of native Zn α_2 gp extracted from (A) prostate and (B) epidermis, as well as of (C) recombinant epidermal Zn α_2 gp. Lane 1, Coomassie-stained gels; the prostate Zn α_2 gp migrated at 38 kDa, while that from the epidermis was at 34 kDa; lane 2, RNase activities demonstrated by zymography; lane 3, corresponding Western blots.

Epidermal Zn α_2 gp, both native and recombinant, has a slightly lower molecular weight (34 kDa) than does prostate Zn α_2 gp (38 kDa); the discrepancy is probably due to posttranslational modifications. To confirm the identification, we include a Western blot probed with antiserum to prostate Zn α_2 gp (Fig. 1 A3, B3, C3); all three molecules strongly react with the antiserum. We have previously reported that both epidermal and prostate Zn α_2 gp have ribonuclease activity [Lei et al., 1998]; so does the recombinant protein, as shown by zymography, upon including RNA in the SDS-PAGE running gel (Fig. 1 A2, B2, C2).

We had previously shown by amino acid sequencing that native epidermal Zn α_2 gp has pyroglutamic acid as the N-terminal [Lei et al., 1998], like plasma Zn α_2 gp [Araki et al., 1988]. We have verified that recombinant Zn α_2 gp has the same N-terminus.

Cell Adhesion to Zn α_2 gp

Zn α_2 gp contains an RGD (Arg-Gly-Asp) sequence at amino acid residues 231–233. RGD sequences are characteristic of many matrix proteins. We assessed whether Zn α_2 gp was an adhesion molecule, using Tu-138 oral epithelial tumor cells. Figure 2 displays the results by phase-contrast microscopy. The least cell spreading occurred on a matrix of BSA (negative control) and most cell spreading on a matrix of Matrigel (positive control). Figure 3 displays the results quantitatively by the MTT assay. Cell binding and spreading was about equal on Zn α_2 gp and on fibronectin, and progressively lower on laminin, vitronectin, and collagens I and IV.

Furthermore, the cells bind and spread on Zn α_2 gp in a dose-dependent fashion, as can be seen by phase-contrast microscopy (Fig. 4) and




Fig. 2. Phase-contrast micrographs of Tu-138 oral carcinoma cells attached to different matrix proteins: (a) BSA (as control), (b) Matrigel, (c) $Zn\alpha_2gp$, (d) fibronectin, (e) vitronectin, (f) laminin, (g) collagen I, and (h) collagen IV.

quantitatively by the MTT assay (Fig. 5). Attachment and spreading increased linearly within the range 2–10 $\mu g/ml$ of $Zn\alpha_2gp$ and peaked at 20 $\mu g/ml$.

Inhibition by RGD Peptides

To demonstrate that the cell binding was specific for the RGD sequence, we ran competitive inhibition assays with the inclusion of RGD peptides. Cell attachment to $Zn\alpha_2gp$ was inhibited by the synthetic peptides RGD, RGDS, and RGDV, in a dose-dependent manner, with optimal inhibition at about 0.2 $\mu g/ml$ of each (Fig. 6). The inhibition was only partial, however, remaining less than a factor of 2 asymptoti-




Fig. 3. Attachment of Tu-138 cells to different matrix proteins (10 $\mu g/ml$), by the MTT assay, as percentage of binding to Matrigel.




Fig. 4. Phase-contrast micrographs of cell attachment to different concentrations of $Zn\alpha_2gp$: (a) BSA control, (b) 10, (c) 20, and (d) 40 $\mu g/ml$ of $Zn\alpha_2gp$.

cally; this finding suggests that there must be other binding sites of consequence.

Inhibition by Antibodies to Specific Integrins

We show by SDS-PAGE and ECL that Tu-138 cells express the integrin subunits β_1 , β_3 , α_5 , and α_v (Fig. 7). To determine which integrins are involved in cell adhesion to $Zn\alpha_2gp$, we performed competitive inhibition assays using antibodies against specific integrins. Antibody




Fig. 5. Dose response of cell attachment to Zn α_2 gp, by the MTT assay.




Fig. 6. Inhibition by RGD peptides of cell attachment to Zn α_2 gp (dose response).

against $\alpha_5\beta_1$ strongly inhibited cell binding; antibody against $\alpha_v\beta_3$ showed a slight inhibition, while those against $\alpha_3\beta_1$ and $\alpha_2\beta_1$ were ineffective (Fig. 8).

Cell Proliferation on a Zn α_2 gp Matrix

We also investigated whether the proliferation of Tu-138 cells was affected by growing the




Fig. 7. Integrin expression in Tu-138 cells, as demonstrated by enhanced chemiluminescence, using antibodies to the subunits (a) β_1 ; (b) β_3 ; (c) α_5 ; and (d) α_v .

cells for four days on different matrix proteins, including Zn α_2 gp. Figure 9 measures cell growth by the MTT assay. We find slight growth inhibition, and only on day 4, for the matrix proteins fibronectin, vitronectin, laminin, and collagens I and IV. On the other hand, cells grown on a Zn α_2 gp matrix are totally growth-inhibited on




Fig. 8. Inhibition of cell attachment to Zn α_2 gp by antibodies to different integrins.

days 1 and 2; they resume their proliferation on days 3 and 4, but at a reduced rate. The cells grown on Zn α_2 gp were viable by trypan blue exclusion.

DISCUSSION

We have shown that Zn α_2 gp functions as a matrix protein for the Tu-138 human oral epithelial squamous cell carcinoma cell line. Adhesion of the cells to Zn α_2 gp and to fibronectin was comparable, while binding to laminin, vitronectin, collagen I, and collagen IV was progressively lower. Binding and spreading of the cells on a Zn α_2 gp matrix occurred in a dose-dependent manner. Attachment to a matrix of Zn α_2 gp was previously reported for the SMKT R-3 cell line [Takagaki et al., 1994]. Adhesion of these human epithelial renal carcinoma cells [Miyao et al., 1989] was greatest on fibronectin, then progressively lower on laminin, vitronectin, Zn α_2 gp, and collagen IV; the order is similar to what we found for the Tu-138 cells, except that Zn α_2 gp ranks considerably lower in binding for the SMKT R-3 cells relative to the other matrix proteins.

Tu-138 cells grew on matrices of fibronectin, laminin, vitronectin, and collagens I and IV at about the same rate as on the BSA control. With Tu-138 cells plated on a Zn α_2 gp matrix, there was a total inhibition of growth for the first 2 days; thereafter, proliferation resumed but at a




Fig. 9. Comparison of growth of Tu-138 cells on different matrix proteins, demonstrating inhibition by Zn α_2 gp, but not by the others.

lower rate. This is the first published observation of an impact of Zn α_2 gp on cell proliferation.

Inhibition of proliferation is often associated with the induction of differentiation, particularly for epithelial cells, but also for adenocarcinomas and others. Zn α_2 gp expression has been correlated with differentiation in various cell types (including those that bind poorly to a Zn α_2 gp matrix). A significant association has been observed between Zn α_2 gp levels and the histological grade of breast cancer tumors, with higher levels found in well-differentiated tumors than in poorly differentiated tumors, by protein assays [Díez-Itza et al., 1993], as well as at the mRNA level [Freije et al., 1991]. Zn α_2 gp mRNA expression is lower in oral squamous cell carcinomas than in normal tissue; among the tumors, it is highest in the better differentiated tumors [Brysk et al., 1999]. Analogously, Zn α_2 gp levels are much higher in benign prostatic hyperplasia than in adenocarcinoma of the prostate [Frenette et al., 1987]. We have found that Zn α_2 gp gene expression is also associated with differentiation in epidermal tumors (with higher levels in normal epithelia than in

squamous cell carcinomas or Merkel cell carcinomas, and higher in the latter than in basal cell carcinomas) [Lei et al., 1997]. In addition, the gene expression of Zn α_2 gp in tumor cell lines is upregulated by agents that induce differentiation, such as interferon- γ [Brysk et al., 1997b] and glucocorticoids [López-Boado et al., 1994].

Matrix proteins can regulate both proliferation and differentiation. Ligation of integrin $\alpha_5\beta_1$ with fibronectin inhibits growth in HT29 colon carcinoma cells [Varner et al., 1995], although the mechanism is undetermined. There is a similar effect of Zn α_2 gp in Tu-138 cells. Signal transduction pathways become activated when specific matrix proteins interact with their cell surface integrin receptors. While cessation of epithelial cell growth is ordinarily accompanied by an increase in differentiation, the two processes can be uncoupled. In epidermal cells, antisense *c-myc* oligomer inhibits growth without inducing differentiation [Hashiro et al., 1991]. Transforming growth factor (TGF- β 1) induces reversible growth arrest of epidermal keratinocytes by inducing *c-myc*, without impacting cellular maturation [Pietenpol et al., 1990].

Another mechanism by which Zn α_2 gp may impact proliferation is our finding that it has ribonuclease activity [Lei et al., 1998]. Some RNases have been used as antitumor agents because they inhibit proliferation. In particular, bovine seminal RNase and frog egg RNase (onconase) have been found to be cytotoxic to tumor cells in vivo and in vitro [Laccetti et al., 1992]. RNase L has been implicated in growth arrest and maturation in embryonal carcinoma cell lines; the carcinoma clones are inhibited preferentially with differentiation [Krause et al., 1985; Silverman, 1994]. The specific RNase activity of Zn α_2 gp is comparable to that of onconase. Zn α_2 gp preferentially cleaves ssRNA substrates and is pyrimidine-specific [Lei et al., 1998], like onconase [Wu et al., 1993]. The N-terminus of both is pyroglutamic acid, which is also the site of the RNase activity of onconase [Wu et al., 1993]. The antiproliferative activity of onconase has been linked to its insensitivity to RNase inhibitors, in contrast to RNase A, which is extremely sensitive to RNase inhibitors and does not exhibit antitumor activity [Wu et al., 1993]. The fact that Zn α_2 gp is only partially inhibited by placental RNase inhibi-

tor suggests that it may, like onconase, escape being neutralized by endogenous inhibitors.

The cell surface receptors of matrix proteins are usually integrins. Combinations of cell-surface integrins allow cells to adhere to, and migrate on, a variety of matrix proteins. Integrins regulate many biological processes, including motility, proliferation, differentiation, and apoptosis [Bates et al., 1995; Ruoslahti, 1996; Zhang et al., 1995; Clarke et al., 1995]. Integrins are transmembrane heterodimers composed of associated α - and β -subunits, the particular combinations of which determine ligand specificity. We found, by ECL, that Tu-138 cells express the integrin subunits α_5 , α_v , β_1 , and β_3 . Using antibodies to specific integrins, we showed that cell binding to Zn α_2 gp was inhibited by an antibody to integrin $\alpha_5\beta_1$, but not by antibodies to integrins $\alpha_v\beta_3$, $\alpha_3\beta_1$, and $\alpha_2\beta_1$.

Many of the β -subunits recognize the tripeptide Arg-Gly-Asp (RGD) in their ligands, which is characteristic of most matrix proteins. Interactions between tumor cells and their substratum play an important role in neoplastic progression. The anchorage-independent growth of tumor cells may be a consequence of transformation-associated changes in intracellular signaling that disrupt integrin-mediated attachment to the substratum [Dedhar, 1995; Ruoslahti, 1996]. Many tumor cells lose their ability to attach to fibronectin after transformation [Wagner et al., 1981; Ruoslahti, 1996]. This may be the result of loss of the fibronectin receptor, integrin $\alpha_5\beta_1$; when $\alpha_5\beta_1$ was transfected into colon tumor cells, which lack the receptor, the cells regained their ability to bind to fibronectin [Varner et al., 1995]. The Tu-138 oral tumor cell line, in contrast to the colon tumor cells, retains its fibronectin receptor. Like fibronectin, Zn α_2 gp contains an RGD peptide sequence. It also has REDI and ILDR sequences similar to the REDV and ILDV cell-recognition regions of fibronectin. Attachment of the Tu-138 cells to Zn α_2 gp was inhibited in a dose-dependent manner by synthetic RGD peptides, by up to about a factor of 2, as had also been found for the SMKT R-3 cells. The incomplete inhibition may be due to residual alternative binding, perhaps to REDI and ILDR sequences in Zn α_2 gp, or may reflect multiple integrin receptors recognizing identical ligands.

The similarities between Zn α_2 gp and fibronectin extend to their integrin receptors: both bind preferentially to integrin $\alpha_5\beta_1$. Despite the com-

mon integrin receptor, however, they are associated with divergent and often opposite functions. Fibronectin inhibits terminal differentiation in epidermal keratinocytes [Adams and Watt, 1989]. On the contrary, Zn α_2 gp expression is higher in well-differentiated cells and decreases with tumor dedifferentiation, as detailed above. The expression of fibronectin increases with tumor progression in some tumors [Sheibani et al., 1991] but decreases in others [Wagner et al., 1981; Ruoslahti, 1996]. Differences in cell binding to fibronectin with tumor progression reflect not only the expression of fibronectin, but also the expression of the fibronectin receptor. When integrin α_5 was transfected into tumor cells not normally containing it, the cells regained their ability to bind to fibronectin [Varner et al., 1995] and the transfectants had an increased rate of proliferation when grown on fibronectin. By contrast, we have found that Zn α_2 gp inhibits proliferation of the Tu-138 cells. These cells express integrin α_5 , and their proliferation is about the same on a matrix of fibronectin as on the BSA control. Fibronectin and Zn α_2 gp are both widespread and abundant endogenous proteins. Their conflicting properties lend interest to their competition for the same integrin receptor.

REFERENCES

- Adams JC, Watt FM. 1989. Fibronectin inhibits the terminal differentiation of human keratinocytes. *Nature* 340:307-309.
- Araki T, Gejyo F, Takagaki K, Haupt H, Schwick HG, Bürgi W, Marti T, Schaller J, Rickli E, Brossmer R, Atkinson PH, Putnam FW, Schmid K. 1988. Complete amino acid sequence of human plasma Zn- α_2 -glycoprotein and its homology to histocompatibility antigens. *Proc Natl Acad Sci USA* 85:679-683.
- Bates RC, Lincz LF, Burns GF. 1995. Involvement of integrins in cell survival. *Cancer Metastasis Rev* 14:191-203.
- Bravo J, Fernández E, Ribó M, de Llorens R, Cuchillo CM. 1994. A versatile negative-staining ribonuclease zymogram. *Anal Biochem* 219:82-26.
- Brysk MM, Lei G, Adler-Storthz K, Chen Z, Brysk H, Tying SK, Arany I. 1999. Zn- α_2 -glycoprotein expression as a marker of differentiation in human oral tumors. *Cancer Lett* 137:117-120.
- Brysk MM, Lei G, Rajaraman S, Selvanayagam P, Rassekh CH, Brysk H, Tying SK, Arany I. 1997a. Gene expression of zinc- α_2 -glycoprotein in normal human epidermal and buccal epithelia. *In Vivo* 11:271-274.
- Brysk MM, Lei G, Selvanayagam P, Brysk H, Tying SK, Arany I. 1997b. Modulation by interferon- γ of zinc- α_2 -glycoprotein gene expression in human epithelial cell lines. *Anticancer Res* 17:3387-3392.
- Bürgi W, Schmid K. 1961. Preparation and properties of Zn- α_2 -glycoprotein of normal human plasma. *J Biol Chem* 236:1066-1074.
- Clarke AS, Lotz MM, Chao C, Mercurio AM. 1995. Activation of the p21 pathway of growth arrest and apoptosis by the beta (4) integrin cytoplasmic domain. *J Biol Chem* 270:22673-22676.
- Dedhar S. 1995. Integrin mediated signal transduction in oncogenesis: an overview. *Cancer Metastasis Rev* 14:165-172.
- Díez-Itza I, Sánchez LM, Allende MT, Vizoso F, Ruibal A, López-Otín C. 1993. Zn- α_2 -glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. *Eur J Cancer* 29A:1256-1260.
- Freije JP, Fueyo A, Uría J, López-Otín C. 1991. Human Zn- α_2 -glycoprotein cDNA cloning and expression analysis in benign and malignant breast tissues. *FEBS Lett* 290:247-249.
- Freije JP, Fueyo A, Uría JA, Velasco G, Sánchez LM, López-Boado YS, López-Otín C. 1993. Human Zn- α_2 -glycoprotein: complete genomic sequence, identification of a related pseudogene and relationship to class I major histocompatibility complex genes. *Genomics* 18:575-587.
- Frenette G, Dubé JY, Lazure C, Paradis G, Chrétien M, Tremblay RR. 1987. The major 40-kDa glycoprotein in human prostatic fluid is identical to Zn- α_2 -glycoprotein. *Prostate* 11:257-270.
- Hashiro M, Matsumoto K, Okumura H, Hashimoto K, Yoshikawa K. 1991. Growth inhibition of human keratinocytes by antisense *c-myc* oligomer is not coupled to induction of differentiation. *Biochem Biophys Res Commun* 174:287-292.
- Krause D, Silverman RH, Jacobsen H, Leisy SA, Dieffenbach CW, Friedman RM. 1985. Regulation of ppp(A2'p)_n A-dependent RNase levels during interferon treatment and cell differentiation. *Eur J Biochem* 146:611-618.
- Laccetti P, Portella G, Mastronicola MR, Russo A, Piccoli R, D'Alessio G, Vecchio G. 1992. In vivo and in vitro growth-inhibitory effect of bovine seminal ribonuclease on a system of rat thyroid epithelial transformed cells and tumors. *Cancer Res* 52:4582-4586.
- Lei G, Arany I, Selvanayagam P, Rajaraman S, Ram S, Brysk H, Tying SK, Brysk MM. 1997. Detection and cloning of epidermal zinc- α_2 -glycoprotein cDNA and expression in normal human skin and in tumors. *J Cell Biochem* 67:216-222.
- Lei G, Arany A, Tying SK, Brysk H, Brysk MM. 1998. Zinc- α_2 -glycoprotein has ribonuclease activity. *Arch Biochem Biophys* 355:160-164.
- Liu T-J, Zhang W-W, Taylor DT, Roth JA, Goepfert H, Clayman GL. 1994. Growth suppression of human head and neck cancer cells by the introduction of wild-type p53 gene via a recombinant adenovirus. *Cancer Res* 54:3662-3667.
- López-Boado YS, Díez-Itza I, Tolivia J, López-Otín. 1994. Glucocorticoids and androgens up-regulate the Zn- α_2 -glycoprotein messenger RNA in human breast cancer cells. *Breast Cancer Res Treat* 29:247-258.
- Miyao N, Tsukamoto T, Kumamoto Y. 1989. Establishment of three human renal cell carcinoma cell lines (SMKT-R-1, SMKT-R-2, and SMKT-R-3) and their characters. *Urol Res* 17:317-324.
- Ohkubo I, Niwa M, Takashima A, Nishikimi N, Gasa S, Sasaki M. 1990. Human seminal plasma Zn- α_2 -glycoprotein: its purification and properties as compared with human plasma Zn- α_2 -glycoprotein. *Biochim Biophys Acta* 1034:152-156.

- Pietenpol JA, Holt JT, Stein RW, Moses HL. 1990. Transforming growth factor β_1 suppression of *c-myc* gene transcription: role in inhibition of keratinocyte proliferation. *Proc Natl Acad Sci USA* 87:3758–3762.
- Poortmans JR, Schmid K. 1968. The level of Zn- α_2 -glycoprotein in normal body fluids and kidney extract. *J Lab Clin Med* 71:807–811.
- Ruoslahti E. 1996. RGD and other recognition sequences for integrins. *Annu Rev Cell Dev Biol* 12:697–715.
- Sánchez LM, López-Otín C, Bjorkman PJ. 1997. Biochemical characterization and crystalization of human Zn- α_2 -glycoprotein, a soluble class I major histocompatibility complex homolog. *Proc Natl Acad Sci USA* 94:4626–4630.
- Sánchez LM, Vizoso F, Díez-Itza I, López-Otín C. 1992. Identification of the major protein components in breast secretions from women with benign and malignant breast diseases. *Cancer Res* 52:95–100.
- Schmid K, Takahashi S. 1964. Polymorphism of zinc- α_2 -human glycoprotein. *Nature* 203:407–408.
- Sheibani N, Rhim JS, Allen-Hoffmann BL. 1991. Malignant human papillomavirus type 16-transformed human keratinocytes exhibit altered expression of extracellular matrix glycoproteins. *Cancer Res* 51:5967–5975.
- Silverman RH. 1994. Fascination with 2–5A-dependent RNase: a unique enzyme that functions in interferon action. *J Interferon Res* 14:101–104.
- Tada T, Ohkubo I, Niwa M, Sasaki M, Tateyama H, Eimoto T. 1991. Immunohistochemical localization of Zn-alpha₂-glycoprotein in normal human tissues. *J Histochem Cytochem* 39:1221–1226.
- Takagaki M, Honke K, Tsukamoto T, Higashiyama S, Taniguchi N, Makita A, Ohkubo I. 1994. Zn- α_2 -glycoprotein is a novel adhesive protein. *Biochem Biophys Res Commun* 201:1339–1347.
- Ueyama H, Deng H-X, Ohkubo I. 1993. Molecular cloning and chromosomal assignment of the gene for human Zn- α_2 -glycoprotein. *Biochemistry* 32:12968–12976.
- Varner JA, Emerson DA, Juliano RL. 1995. Integrin $\alpha_5\beta_3$ expression negatively regulates cell growth; reversal by attachment to fibronectin. *Mol Biol Cell* 6:725–740.
- Wagner D, Ivatt R, Destree A, Hynes R. 1981. Similarities and differences between fibronectins of normal and transformed hamster cells. *J Biol Chem* 256:11708–11715.
- Wu YN, Mikulski SM, Ardelt W, Rybak SM, Youle RJ. 1993. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. *J Biol Chem* 268:10686–10693.
- Zhang Z, Vuori K, Reed JC, Ruoslahti E. 1995. The $\alpha_5\beta_1$ integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. *Proc Natl Acad Sci USA* 92:6161–6165.